Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
about
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeThe effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.Immunoglobulin replacement therapy in secondary hypogammaglobulinemiaCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabDifferential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosusLow immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving RituximabIL-1β processing in mechanical ventilation-induced inflammation is dependent on neutrophil factors rather than caspase-1Hypogammaglobulinemia in pediatric systemic lupus erythematosus.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisLong-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).Impact of rituximab trials on the treatment of ANCA-associated vasculitis.Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.Infectious complications of rituximab therapy in renal disease.Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.[Treatment strategies for ANCA-associated vasculitides].Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil.Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides.Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.
P2860
Q26776308-30F77C77-E429-4153-8ADB-12DB12611B51Q27025692-7DE41C0F-4B39-497E-83EF-CD0E6C8B5FD8Q33419638-089F8595-9202-45BA-8C0A-78ACD23F17D0Q33683956-1C371CD4-72F8-446F-8037-6852FBD20961Q33706447-EEB2EA95-F1F9-4EE5-9E36-F4E586B173AFQ33817252-6DBAA921-6F3F-4C68-B988-BEB5925A574FQ33980153-E593EC97-3289-4808-9370-F1391A81BFCBQ34652046-DE524EBC-B164-4827-B31F-F82F70B23F39Q35065425-DFCD3A69-AA3F-4216-937F-7673B64A091EQ35577284-7B4AFA89-4350-4A44-9A5B-E7B39B0B4A2BQ35887318-D81C0499-70F0-4650-AB4C-85C947195BD1Q36538948-B166955F-F995-4F1F-81EE-295F146DBB87Q36702336-6B957435-C4A0-4F6A-9282-DA250CB1342DQ37342980-591C1728-BB1F-4224-AD62-0F4C8BDB3811Q37640836-396572F8-8E60-45E1-B71B-D968FD6DD27CQ37682245-029B6BA6-77BE-4075-A011-9CAD3C32129FQ37690935-4DD4494A-18D7-4D5B-9232-ADB60BDAAD1AQ38152651-A5667F31-9757-4BF2-8DEB-4A34403FDC94Q38334787-A83C0421-D5FF-4421-9BE2-3D3E27E158C6Q38548417-2237232F-9557-4EA3-B49A-2941F2F45AD8Q38569860-9900946D-06CD-441E-B2BB-8355BA33FBD0Q39045194-981D8242-3D17-4E8C-B321-2E9EA9DF7783Q39088103-2DF73EBB-E7E6-434C-B3F6-9FEEE5D11E1AQ40065728-D2AF864C-CB08-4514-87F8-DCAE3D30FB20Q40075352-ADEEDBBE-3499-42EB-941C-1B3D72481D4CQ40211205-B8BB1CDD-CCB1-443E-910A-E09C9FB665ECQ40393067-E6AC8935-81CA-44F5-86A8-7E661F351DA0Q40684657-B4008707-5E94-41B1-8428-65C2B531FDECQ41192540-0015A125-8379-4602-99E8-172B5124738CQ41208157-8AD5FB41-B3E1-4E44-BF38-BC54FBCA1657Q41667048-25FEC96B-9D57-4085-AD4A-87262D24E1ECQ42261957-9ECAC288-830C-4FAC-85E9-4C214CCDFA2EQ42926715-86EA48CD-BC2E-4A32-B4FB-C95BEDEAF466Q43416268-716CC830-954A-4E88-97EE-0C2EE3C662DCQ45231147-D9429DDB-875A-410C-A002-0353EAB198D5Q45994929-787EB745-3892-4405-916C-D9620E594CD7Q47105115-640E3DAF-42F2-45DA-BE3C-330F23E17800Q50850119-E5726E69-CE14-4CFC-B6D6-5D4233F3F103Q50897604-90ECD49B-C358-4A2E-9214-6D9A9133F3D6Q55340553-C2DD53C7-D81F-4C42-8CF1-2F1D8C5244C4
P2860
Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@ast
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@en
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@nl
type
label
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@ast
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@en
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@nl
prefLabel
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@ast
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@en
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@nl
P2093
P2860
P1433
P1476
Impact of rituximab on immunog ...... ANCA-associated vasculitides.
@en
P2093
Dirk Lebrecht
Hans Hartmut Peter
Jens Thiel
Klaus Warnatz
Michael Schlesier
Nils Venhoff
Nora M Effelsberg
Reinhard E Voll
P2860
P304
P356
10.1371/JOURNAL.PONE.0037626
P407
P577
2012-05-21T00:00:00Z